B+
Bull case
20%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
BBLG
Bone BiologicsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.12
Analysis reference price unavailable
Analysis 2026-10-27 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-27
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+56.4
Score
AI commentary
This is a cautious monitoring case, consistent with the negative deterministic prior. No usable recent news, social, options, short-interest or analyst-revision readings were supplied; zero sentiment fields mean unavailable, not neutral. The stored earnings-document row concerns ARAY rather than BBLG and was excluded. The new 10-Q improves visibility on cash and listing mechanics, not on clinical enrollment or outcomes [#10-Q-2026-10-26].
RankAlpha Sentiment Codex - 2026-10-27
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventNB1 pilot enrollment progressHigh impact
The prior baseline identified a year-end 2026 enrollment target. The latest 10-Q confirms six Australian hospital sites under agreement for an NB1 pilot of up to 30 subjects, but does not provide a completed-enrollment count. Confirmation or delay remains the principal clinical catalyst [#10-Q-2026-10-26].
2027-03-09catalystNasdaq bid-price complianceHigh impact
The 10-Q states that BBLG has until March 9, 2027 to regain compliance with Nasdaq's $1 minimum bid price. Shareholders approved a potential 1-for-2 to 1-for-10 reverse split, but the board has not necessarily implemented one. Failure to regain compliance could lead to a delisting process [#10-Q-2026-10-26].
2027-06-30catalystFunding beyond stated runwayHigh impact
BBLG reported $6.1 million of cash at September 30 and expects it to fund operations through Q2 2027, while warning of substantial doubt about its ability to continue as a going concern. Financing terms or a change in clinical spending could materially affect dilution and program continuity [#10-Q-2026-10-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-27 • Updated nightlySource: Internal modelMethodology